Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-05221304 Formulation A · 1 trial · 1 indication
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)
Maximum Observed Plasma Concentration (Cmax)
| Arm | Type | Description |
|---|---|---|
| PF-05221304 Formulation A | EXPERIMENTAL | - |
| PF-05221304 Formulation B | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| PF-05221304 Formulation A | DRUG | 50mg |
| PF-05221304 Formulation B | DRUG | 50mg |
Inclusion Criteria: * Ages of 18 and 55 years old inclusive * Body Mass Index (BMI) of \>= 17.5 and \<= 30.4 kg/m2 * Total body weight \> 50 kg (110lb) Exclusion Criteria: * Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular,...
PF-05221304 Formulation A is an investigational small molecule developed by Pfizer, Inc. It is a specific formulation of PF-05221304 that was studied in a Phase 1 bioavailability trial comparing it against another formulation of the same compound in healthy adult volunteers.
Pfizer, Inc. is developing PF-05221304 Formulation A. Pfizer trades on the New York Stock Exchange under the ticker PFE. The company sponsored the Phase 1 bioavailability study of this formulation.
PF-05221304 Formulation A is in Phase 1 development. It is investigational and has not been approved by the FDA. The single Phase 1 trial of this formulation has been completed, and no trials of it are currently active.
PF-05221304 Formulation A was studied in NCT03871439, an open label, two period Phase 1 study comparing the bioavailability of two different formulations of PF-05221304 in healthy adults. The trial enrolled 10 participants in the United States and has been completed.
NCT03871439 was an open label, two period bioavailability study of PF-05221304 Formulation A in healthy adults aged 18 years and older. It was a controlled, randomized trial with 10 participants, conducted in the United States, and it has been completed.